w4lEvwDV
type: Answer
type: WrittenAnswer
answer has question: 0dD1BhkB
answer has answering person: ueCA7LxD
answer text: Eculizumab (Soliris) has undergone assessment for the indication of atypical haemolytic uremic syndrome via a Europe-wide centralised variation procedure. The Committee for Medicinal Products for Human Use, as well as the Commission on Human Medicines (UK) considered, and have recommended the granting of the extension of indication. Eculizumab is now licensed for the indication.
answer given date: 2012-01-16+00:00
answer has answering body: qjSEa2Ms
written answer has answering body: qjSEa2Ms